Drug Database · Clinicians

Glimepiride + Metformin

Brands (8) Gliformin, Glucopride, Lupimet…Show all

Oral hypoglycemic (Sulfonylurea/Biguanides combination); Oral hypoglycemic agent; and others PH FDA category
Fixed-dose combination.

Rx · Prescription drug11 PH productsVAT-exempt
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
US label not yet available for this generic. Check the Philippine package insert (linked in the products table where the FDA has published one).

Component information

No US or EU label exists for this exact combination, so information is shown for each component.

  • Use: Glimepiride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [see Clinical Studies (14.1) ] . US FDA label

    Kidney dosing: Glimepiride (single-agent)
    Show full dosing details
    CrCl ≥60 mL/min
    Start 1 or 2 mg once daily with breakfast; increase by 1 to 2 mg every 1 to 2 weeks; maximum 8 mg/day (label). Older adults: start 1 mg.
    CrCl 30–59 mL/min
    Start 1 mg once daily and titrate slowly (label 2.1, 8.6): hypoglycemia risk is higher in kidney impairment, and the M1 and M2 metabolites accumulate (M1 AUC 2.3-fold and M2 AUC 8.6-fold higher at CrCl <20). Studied at CrCl 10–60 mL/min with doses of 1 to 8 mg.
    CrCl 15–29 mL/min
    Start 1 mg once daily and titrate slowly (label 2.1, 8.6): hypoglycemia risk is higher in kidney impairment, and the M1 and M2 metabolites accumulate (M1 AUC 2.3-fold and M2 AUC 8.6-fold higher at CrCl <20). Studied at CrCl 10–60 mL/min with doses of 1 to 8 mg.
    CrCl <15 mL/min (not on dialysis)
    Start 1 mg once daily and titrate slowly (label 2.1, 8.6): hypoglycemia risk is higher in kidney impairment, and the M1 and M2 metabolites accumulate (M1 AUC 2.3-fold and M2 AUC 8.6-fold higher at CrCl <20). Studied at CrCl 10–60 mL/min with doses of 1 to 8 mg. No separate advice for CrCl <15; hypoglycemia can be prolonged. Specialist judgment.
    Hemodialysis (intermittent)
    Not studied in dialysis; the label gives no dialysis dose. Removal by hemodialysis unlikely (over 99.5% protein-bound). Specialist input; prefer agents with lower hypoglycemia risk.
    Peritoneal dialysis
    Not studied; no dose in label. Specialist input. Metabolites accumulate in kidney impairment; risk of prolonged hypoglycemia (label 8.6, 12.3).
    CRRT
    No data. Specialist input; insulin usually preferred in acute illness.
    • Dialyzable? Not stated; unlikely (protein binding over 99.5%; label).
    • Monitoring Blood glucose (hypoglycemia, which can be prolonged), hemoglobin A1c, kidney function. Hold in acute illness with poor intake.

    From the Glimepiride monograph (renalcarematters.com, reviewed).

  • Use: Metformin Hydrochloride Tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. US FDA label

    Kidney dosing: Metformin (single-agent)
    Show full dosing details
    eGFR ≥60
    Usual dosing. Assess kidney function before starting and periodically (label).
    eGFR 30–59
    eGFR 45–59: usual dose; consider dose reduction if at high risk of lactic acidosis. eGFR 30–44: label advises not to start; if continuing, reduce to a maximum of 1,000 mg/day (KDIGO 2022; ADA-KDIGO 2022). Recheck eGFR every 3 to 6 months.
    eGFR 15–29
    Contraindicated (label). Stop if eGFR falls below 30.
    eGFR <15 (not on dialysis)
    Contraindicated (label).
    Hemodialysis (intermittent)
    Contraindicated (eGFR <30 per label).
    Peritoneal dialysis
    Contraindicated (eGFR <30 per label).
    CRRT
    Not appropriate; contraindicated in severe kidney impairment (label).
    • Dialyzable? Yes: dialyzable with clearance up to 170 mL/min under good hemodynamic conditions; hemodialysis may help remove drug in suspected overdose (label).
    • Monitoring eGFR before starting and at least periodically; more often in older adults. Stop before or at the time of iodinated contrast in at-risk patients per label. Hold temporarily during acute illness with dehydration, sepsis, hypoxia or acute heart failure, during procedures with restricted food or fluid intake, and for acute kidney injury; restart when eating and kidney function is stable (label 5.1).

    From the Metformin monograph (renalcarematters.com, reviewed).

Note: Fixed-dose combinations may not allow the dose changes advised for each component; check the strength and use the single agents if a component needs adjusting.

Dosing: Altered kidney function

No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.

Kidney dosing for each component (single-agent) is shown under Component information.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosage forms

Philippines

  • Sustained-release tablet: 2 mg/500 mg
  • Film-coated tablet: 2 mg/500 mg
  • Prolonged-release tablet: 2 mg + 500 mg, 2 mg/500 mg
  • Extended-release tablet: 2 mg/500 mg
  • Tablet: 2 mg/500 mg

Registered products in the Philippines

11 products registered with the Food and Drug Administration (FDA) Philippines list Glimepiride + Metformin as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products11
Philippine FDA-registered products for Glimepiride + Metformin
Package insert
GliforminGlimepiride + Metformin hydrochloride
2 mg/ 500 mg Film-Coated TabletAlu/PVC Transparent/Colorless Blister Pack of 10's (Box of 30's)
RxVAT-exempt
GENUONE Sciences IncRepublic of Korea
ARISTO PHARMA PHILIPPINES, INCImporter: Medethix, Inc
DRP-8089
Feb 6, 2029
GlucoprideGlimepiride + Metformin Hydrochloride
2 mg/500 mg Sustained-Release TabletAlu/PVC Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Wallace Pharmaceuticals Pvt. LtdIndia
Hexagon Pharmaceuticals
DRP-16335
Feb 7, 2030
LupimetGlimepiride + Metformin Hydrochloride
2 mg/500 mg Sustained-Release TabletAlu/PVC/PVDC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Inventia Healthcare LimitedIndia
Multicare Pharmaceuticals Phils. Inc.Importer: I.E. Medica, Inc.
DRP-9979
Feb 4, 2029
NoneGlimepiride + Metformin Hydrochloride
2 mg/ 500 mg Film-Coated TabletAlu/PVC Transparent/Colorless Blister Pack of 10's Box of 30's
RxVAT-exempt
Genuone Sciences Inc.Republic of Korea
Actimed Inc.Importer: Medethix Inc.
DRP-8088
Feb 6, 2029
NoneGlimepiride + Metformin hydrochloride
2 mg/500 mg Extended-Release TabletAlu/PVC Blister Pack x 10's (Box of 3 blister packs x 10 tablets; Box of 10 blister packs x 10 tablets)
RxVAT-exempt
Innova Captab LimitedIndia
TGP Pharma Inc.Importer: Medethix, Inc.Trader: Aztec Pharma Pvt. Ltd.
DRP-6696-01
Mar 26, 2029
NoneGlimepiride + Metformin hydrochloride
2 mg/500 mg Sustained-Release TabletAlu/PVC-PVDC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Inventia Healthcare LimitedIndia
RiteMED Phils, Inc.Importer: Unilab, Inc.
DRP-14727-01
Dec 14, 2028
Norizec PlusGlimepiride + Metformin Hydrochloride
2 mg/500 mg Sustained-Release TabletBlister Pack x 10s
RxVAT-exempt
Inventia Healthcare LimitedIndia
UNILAB, Inc.
DRP-14727
Dec 14, 2028
Perglim M-2Glimepiride + Metformin Hydrochloride (In Sustained-Release Form)
2 mg/500 mg TabletAlu/Clear PVC/PVDC Blister Pack x 20's in an individual box x 20's (Box of 100's)
RxVAT-exempt
INVENTIA HEALTHCARE LIMITEDIndia
METRO DRUG, INC.Importer: MEGA LIFESCIENCES LIMITED INC.Trader: MEGA LIFESCIENCES (AUSTRALIA) PTY. LTD.
DR-XY38994
Jan 27, 2029
PirminGlimepiride + Metformin Hydrochloride (in Extended Release form)
2mg + 500mg Prolonged-Release TabletAlu/PVC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Globela Pharma Pvt. Ltd.India
AMB HK Enterprises, Inc.
DRP-18917
Sep 30, 2031
Proglutrol G2Glimepiride + Metformin Hydrochloride
2 mg/ 500 mg Sustained-Release TabletAlu-PVC/PVDC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Inventia Healthcare LimitedIndia
Healol Pharma Corporation
DRP-15381
Jun 28, 2029
Solosamet SRGlimepiride + Metformin Hydrochloride
2 mg/500 mg Prolonged-Release TabletAluminum/PVC/PVDC/PE Blister Pack x 10's (Box of 10's and 30's) as commercial and physician's sample
RxVAT-exempt
Handok Inc.Republic of Korea
Importer: Sanofi-Aventis Philippines, Inc.
DRP-5214
Sep 6, 2031

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .